Genmab
1.322
DKK
-0,23 %
Mindre end 1K følgere
GMAB
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
-0,23%
-17,27%
-11,42%
-10,98%
-17,63%
-36,5%
-44,15%
-1,56%
+3.776,83%
Genmab er et farmaceutisk selskab. Virksomheden har specialiseret sig i forskning og udvikling af antistoffer, som hovedsageligt bruges til behandling af kræftpatienter med lymfatisk leukæmi og solide tumorer. Forskning og udvikling er baseret på virksomhedens egen udviklede tekniske platform, og driften foregår på globalt plan. Genmab blev grundlagt i 1999 og har sit hovedkontor med beliggenhed i København.
Læs mereMarkedsværdi
87,51 mia. DKK
Aktieomsætning
145,04 mio. DKK
Omsætning
21,53 mia.
EBIT %
31,14 %
P/E
10,82
Udbytteafkast, %
-
Finanskalender
8.5
2025
Delårsrapport Q1'25
7.8
2025
Delårsrapport Q2'25
6.11
2025
Delårsrapport Q3'25
Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
Capital Increase in Genmab as a Result of Employee Warrant Exercise
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
Notice to Convene the Annual General Meeting of Genmab A/S
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Genmab Publishes 2024 Annual Report
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
